Study summary
Guselkumab closed fistulas in more than a quarter of people
28.3% vs 10.3%had fistulas fully closed at 24 weeks, guselkumab vs placebo
What was tested
Guselkumab, an injection that blocks IL-23, against placebo in people with Crohn's fistulas around the anus, one of the hardest complications to treat.
What they found
- Fistulas were fully closed, with no fluid on MRI, in 28.3% on the lower dose and 27.0% on the higher dose, against 10.3% on placebo.
- Results are for 24 weeks. Whether closure lasts is not yet known.
- It is the first drug of its class shown to work for fistulas in a dedicated trial.
What it means
A second well-proven option for fistulas, where infliximab has been the main choice.
Last reviewed 2026-11-14 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.